GRFS News & Events

Grifols says its Strategy Committee has proposed, and the board has approved, the initial public offering on the U.S. stock market of a portion of the shares of the company's U.S. Biopharma business. If the transaction is successfully completed, Grifols would float a minority stake in Grifols' Biopharma U.S. The parent company, Grifols S.A., would maintain its listing in Spain and would retain control of the U.S. business. The proposed IPO is intended to raise capital to "support the company's strategic priorities, including debt reduction and investment in growth across key markets where it is advancing its self-sufficiency projects." Grifols says it will continue to grow its plasma and diagnostics businesses in other markets, "with improved profit margins from our self-sufficiency programs in Egypt and Canada and growing revenues from new products." Shares of Grifols are up 6% to $8.05 in premarket trading.

According to a regulatory filing, Grifols reported that, as a consequence of Grifols' self-sufficiency programs for its Biopharma businesses, its Board of Directors has decided to initiate a process to evaluate a potential Initial Public Offering in the United States of a portion of the shares of its subsidiary and parent of its U.S. Biopharma business. Any such transaction remains subject to, among other things, regulatory and legal requirements, internal approvals and market conditions. There can be no assurance that any IPO will be undertaken or completed by the company. Regardless of any such IPO being undertaken or completed, Grifols will continue to trade in Spain through the automated information system.

Grifols shared proof-of-concept data from its Chronos-PD program, demonstrating that biological changes in individuals with Parkinson's disease occur more than a decade before clinical diagnosis, with potential future implications for early detection and intervention. The data has been published as part of a publication in medRxiv and will be shared at the AD/PD 2026 conference in Copenhagen. Chronos-PD is a program driven by Grifols' subsidiary Alkahest designed to identify early signs of PD years before clinical diagnosis. The proof-of-concept study analyzed over 2,600 longitudinal plasma samples from PD cases and controls, and measured over 25,000 protein types using four complementary proteomics platforms. Researchers have confirmed PD biomarkers previously discovered and identified reproducible early PD biomarkers, validated across up to 5 independent cohorts. The study also uncovered novel, early biomarkers of PD. Chronos-PD shows that biological changes associated with PD can emerge up to 12 years before clinical diagnosis. Uncovered reproducible early molecular signals and distinct molecular patterns in PD, supporting future efforts in patient stratification and precision medicine research. Chronos is part of a broad Grifols program to find early disease biomarkers leveraging more than 100 million proprietary plasma samples connected to real-world data on thousands of conditions.